C B Baker

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi Best practices: racial and ethnic effects on antipsychotic prescribing practices in a community mental health center
    Scott W Woods
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06515, USA
    Psychiatr Serv 54:177-9. 2003
  2. ncbi Cost of treatment failure for major depression: direct costs of continued treatment
    C B Baker
    Yale School of Medicine, Department of Psychiatry, Connecticut Mental Health Center, USA
    Adm Policy Ment Health 28:263-77. 2001
  3. ncbi Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis
    C Bruce Baker
    Yale University School of Medicine, Department of Psychiatry, Connecticut Mental Health Center, New Haven 06519, USA
    Depress Anxiety 17:1-9. 2003
  4. ncbi Is there a SSRI dose response in treating major depression? The case for re-analysis of current data and for enhancing future study design
    C Bruce Baker
    Yale University School of Medicine, Department of Psychiatry, Connecticut Mental Health Center, Treatment Research Program, New Haven 06519, USA
    Depress Anxiety 17:10-8. 2003
  5. ncbi Quantitative analysis of sponsorship bias in economic studies of antidepressants
    C Bruce Baker
    Department of Psychiatry, Yale School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut 06519, USA
    Br J Psychiatry 183:498-506. 2003
  6. ncbi Does the manic/mixed episode distinction in bipolar disorder patients run true over time?
    S W Woods
    Department of Psychiatry, Treatment Research Program, Connecticut Mental Health Center, Yale University School of Medicine, 34 Park St, New Haven, CT 06519, USA
    Am J Psychiatry 158:1324-6. 2001
  7. ncbi Mood-stabilizer-maintained, remitted bipolar patients: taper and discontinuation of adjunctive antipsychotic medication
    John R Saksa
    Department of Psychiatry, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA
    Gen Hosp Psychiatry 26:233-6. 2004
  8. ncbi Control group bias in randomized atypical antipsychotic medication trials for schizophrenia
    Scott W Woods
    Treatment Research Program, Department of Psychiatry and Biostatistics Division, Yale University School of Medicine, New Haven, Conn. 06519, USA
    Arch Gen Psychiatry 62:961-70. 2005
  9. ncbi Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study
    Scott W Woods
    Department of Psychiatry, Yale University, Connecticut Mental Health Center, New Haven 06519, USA
    J Clin Psychiatry 69:546-54. 2008

Research Grants

  1. IMPROVING DEPRESSION TREATMENT WITH PRACTICE GUIDELINES
    C Baker; Fiscal Year: 2004

Detail Information

Publications9

  1. ncbi Best practices: racial and ethnic effects on antipsychotic prescribing practices in a community mental health center
    Scott W Woods
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06515, USA
    Psychiatr Serv 54:177-9. 2003
  2. ncbi Cost of treatment failure for major depression: direct costs of continued treatment
    C B Baker
    Yale School of Medicine, Department of Psychiatry, Connecticut Mental Health Center, USA
    Adm Policy Ment Health 28:263-77. 2001
    ..These results suggest that in settings similar to the present study, antidepressant treatments with higher failure rates may carry a marked hidden cost disadvantage...
  3. ncbi Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis
    C Bruce Baker
    Yale University School of Medicine, Department of Psychiatry, Connecticut Mental Health Center, New Haven 06519, USA
    Depress Anxiety 17:1-9. 2003
    ..Study designs better tailored to address the relevant clinical question would test these hypotheses more appropriately than previous studies...
  4. ncbi Is there a SSRI dose response in treating major depression? The case for re-analysis of current data and for enhancing future study design
    C Bruce Baker
    Yale University School of Medicine, Department of Psychiatry, Connecticut Mental Health Center, Treatment Research Program, New Haven 06519, USA
    Depress Anxiety 17:10-8. 2003
    ..This re-analysis is performed in a companion article [Baker et al. 2003, Depress Anxiety 17:1-9]...
  5. ncbi Quantitative analysis of sponsorship bias in economic studies of antidepressants
    C Bruce Baker
    Department of Psychiatry, Yale School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut 06519, USA
    Br J Psychiatry 183:498-506. 2003
    ..Concern is widespread about potential sponsorship influence on research, especially in pharmacoeconomic studies. Quantitative analysis of possible bias in such studies is limited...
  6. ncbi Does the manic/mixed episode distinction in bipolar disorder patients run true over time?
    S W Woods
    Department of Psychiatry, Treatment Research Program, Connecticut Mental Health Center, Yale University School of Medicine, 34 Park St, New Haven, CT 06519, USA
    Am J Psychiatry 158:1324-6. 2001
    ..The authors sought to determine whether the manic/mixed episode distinction in patients with bipolar disorder runs true over time...
  7. ncbi Mood-stabilizer-maintained, remitted bipolar patients: taper and discontinuation of adjunctive antipsychotic medication
    John R Saksa
    Department of Psychiatry, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, USA
    Gen Hosp Psychiatry 26:233-6. 2004
    ..When adjunctive antipsychotic medications are discontinued, bipolar patients' clinical symptoms can remain unchanged. Others are, however, at risk for manic relapse...
  8. ncbi Control group bias in randomized atypical antipsychotic medication trials for schizophrenia
    Scott W Woods
    Treatment Research Program, Department of Psychiatry and Biostatistics Division, Yale University School of Medicine, New Haven, Conn. 06519, USA
    Arch Gen Psychiatry 62:961-70. 2005
    ....
  9. ncbi Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study
    Scott W Woods
    Department of Psychiatry, Yale University, Connecticut Mental Health Center, New Haven 06519, USA
    J Clin Psychiatry 69:546-54. 2008
    ..The goal of this study was to evaluate the efficacy and safety of levetiracetam versus placebo for tardive dyskinesia (TD)...

Research Grants1

  1. IMPROVING DEPRESSION TREATMENT WITH PRACTICE GUIDELINES
    C Baker; Fiscal Year: 2004
    ....